新型抗病毒药物防治移植患者巨细胞病毒感染的研究进展

Research Progress of Novel Antiviral Drugs in the Treatment and Prevention of Cytomegalovirus Infection in Transplant Patients

巨细胞病毒(CMV)是器官移植后最常见的感染源。除感染外,CMV还增加器官移植并发症的风险,导致移植失败率和死亡率升高。CMV感染的预防和治疗对于移植的结局至关重要。最近出现了几种新型抗病毒药物,包括来特莫韦、马立巴韦和布林西多福韦,为移植患者抗CMV感染提供了新的治疗选择。

Cytomegalovirus(CMV)is the most common source of infection after organ transplantation.In addition to infection,CMV increases the risk of organ transplant complications,leading to higher rates of transplantation failure and mortality.Prevention and treatment of CMV infection are critical to the outcome of transplantation.Several new antiviral agents have recently emerged,including letermovir,maribavir,and brincidofovir,offering new treatment options for transplant patients against CMV infection.